Skip to main content
Third-party tested
Purity documentation available
Research supply chain
Compliance notice included
Tesamorelin
99%+ Purity

Tesamorelin Peptide

Tesamorelin is a synthetic 44-amino acid growth hormone-releasing hormone (GHRH) analogue approved by the FDA in 2010 for treating HIV-associated lipodystrophy. The peptide features enhanced stability through N-terminal modification, providing greater resistance to enzymatic degradation than endogenous GHRH. Clinical trials demonstrate tesamorelin reduces visceral adipose tissue by 15-20% over 26 weeks while preserving physiological GH pulsatility. Research shows the peptide increases lean muscle mass and density, improves lipid profiles, reduces cardiovascular risk markers including carotid intima-media thickness, and enhances cognitive function in adults with mild cognitive impairment and healthy older adults through modulation of brain neurotransmitters. For Research Use Only. Not intended for human or veterinary use.

We accept

Certificate of Analysis

Third Party TestedISO/IEC 17025 Accredited
ISO 170253rd Party
99.691%
Purity
Passed full QC panel
TestedFeb 20, 2026
Full QC Panel
Purity (HPLC)99.691%
ISO/IEC 17025 Accredited

Compound Information

Structured specifications and handling data

Molecular profile

Technical specifications

Type:GHRH Analog Peptide
CAS Number:218949-48-5
Molecular Weight:5135.86 g/mol
Amino Acids:44
Sequence:N-((3E)-hex-3-enoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Formula:C221H366N72O67S
PubChem Database
Storage requirements

Stability and handling

Lyophilized
Cold Storage
Light Sensitive
Storage TemperatureStore in a cool, dry place away from light; refrigerate at 2–8°C (36–46°F)
ReconstitutionSterile water or bacteriostatic water recommended
StabilityStable when stored properly; avoid repeated freeze-thaw cycles
Chemical structure

Molecular model

3D Interactive

Loading 3D Molecule...

Left click to rotate • Scroll to zoom

Tesamorelin research overview

Tesamorelin is built on the full 44 amino acid sequence of natural GHRH, with one key modification: a trans-3-hexenoic acid group attached to the very first amino acid. This small lipid tag improves the peptide's stability, letting it remain active longer than unmodified GHRH in experimental settings. Natural GHRH is the hormone the hypothalamus uses to tell the pituitary gland to release growth hormone, and Tesamorelin mimics that signal.

When Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, it triggers a signaling chain that starts with cyclic AMP production and leads to growth hormone release. In animal studies, researchers have tracked these growth hormone pulses over time using serial blood sampling. They have also measured downstream effects on IGF-1, a molecule the liver produces in response to growth hormone that circulates throughout the body and influences many cell types.

Tesamorelin research has also explored how growth hormone axis activation relates to body composition and visceral fat measurements in animal models. It is one of the more thoroughly studied GHRH analogs in published literature, giving researchers a well-characterized tool for investigating pituitary signaling and the growth hormone-IGF-1 axis. For Research Use Only. Not intended for human or veterinary use.

Receptor Binding Studies

Has been investigated for interactions with GHRH receptors in pituitary cell preparations and binding assays.

Adenylyl Cyclase Signaling

Research has explored effects on cyclic AMP production in cell-based receptor activation experiments.

Hormone Secretion Patterns

Animal studies have examined pulsatile growth hormone release using serial sampling methodologies.

IGF-1 Measurements

Research has tracked downstream insulin-like growth factor levels in endocrine pharmacology studies.

Research evidence

Published studies and concise summaries for research review.

Research Paper
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
Falutz J et al.
View Paper
Research Paper
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

AI-generated summary of this research paper below.

This pivotal phase 3 randomized, double-blind, placebo-controlled trial (published in NEJM) evaluated subcutaneous tesamorelin (2 mg daily) versus placebo in 412 HIV-infected adults with abdominal fat accumulation over 26 weeks, followed by a 26-week extension where placebo patients switched to tesamorelin. Tesamorelin significantly reduced visceral adipose tissue (VAT) by 15.2% (vs +5.0% increase with placebo; P<0.001), improved lipid profiles (reduced triglycerides by 50 mg/dL and non-HDL cholesterol), and enhanced patient-reported body image without worsening subcutaneous fat loss. Glucose parameters remained stable overall, though some patients showed transient increases. The treatment was well tolerated, with mild injection-site reactions and arthralgias as the most common side effects. This study established tesamorelin as the first FDA-approved therapy for HIV-associated lipodystrophy, demonstrating its ability to selectively target harmful visceral fat while preserving metabolic safety.
Research overview
Total Papers
110+
Year Range
2003+
Research status
Active
Peer-reviewed studies available
Research FAQ

Frequently asked questions

Concise answers about laboratory context, handling, and documentation for this compound.

Laboratory compliance notice

All compounds sold by Validated Peptides are intended for in-vitro laboratory research only.

These materials are not approved by the FDA for human or animal use and are not intended for diagnostic, therapeutic, or clinical applications.

Purchasers are responsible for compliant handling, storage, and use within an appropriate laboratory environment.

Research Use Only
Not for Human Use
21+ Required